Background Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of reproductive age. Its clinical expression is diverse, including metabolic, behavioral, and reproductive effects, with many affected by obesity and decreased quality of life. Women with PCOS who have undergone surgically induced weight loss have reported tremendous benefit, not only with weight loss, but also improvement of hyperandrogenism and menstrual cyclicity.
Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age, with estimates of prevalence as high as 15 % [1] . There is a broad spectrum of phenotypes, but all have a combination of oligo-or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovaries [2] . PCOS is associated with an increased risk of metabolic disturbances including insulin resistance and hyperinsulinemia, impaired glucose tolerance, gestational diabetes, and type 2 diabetes (T2DM) [3, 4] , with all of these exacerbated by obesity [1] . Reproductive comorbidities include infertility [1] and increased risk of endometrial cancer [5] due to oligo-or anovulation. Other health risks include cardiovascular disease [6, 7] , dyslipidemia [8] , nonalcoholic fatty liver disease [9] , and sleep apnea [10] . Stress-related psychiatric disorders, including depression and anxiety, are also associated with PCOS [11, 12] . It is unclear whether this association is due to psychosocial elements or directly related to the etiology of PCOS. Given its unknown etiology, treatment for PCOS is focused on alleviating symptoms.
Obesity is associated with PCOS and exacerbates many of its comorbidities [1] . Obesity affects approximately one third of US adults (BMI≥30 kg/m 2 ) [13] , with few effective treatments. Weight loss from the traditional lifestyle modification method of diet and exercise is not commonly achieved nor sustained [14] [15] [16] . Though a healthy lifestyle can improve the symptoms of PCOS (i.e., insulin resistance, body composition, and hyperandrogenism), there is little evidence that it improves glucose tolerance, lipid profiles, reproductive outcomes, or quality of life [17] . Additionally, pharmacologic weight loss agents are limited and are associated with relatively small amounts of weight loss [18] .
Bariatric surgery has gained popularity as an effective weight loss treatment. It causes substantial, sustained weight loss superior to other weight loss strategies. Furthermore, bariatric surgery reduces the incidence of T2DM [19] , heart disease [20] , and cancer [21] . For many, it also eliminates the need for pharmacological treatment of T2DM, hypertension, and hyperlipidemia [22] . Promising but limited data suggest that bariatric surgery may be an effective treatment option in women with PCOS. PCOS women undergoing Roux-en-Y gastric bypass (RYGB) or biliopancreatic diversion lost weight and had improved insulin resistance, restoration of regular menstrual cycles, and improved or resolved clinical and biochemical hyperandrogenism [23, 24] .
The goal of the present study was to determine whether surgically induced weight loss was able to reverse the metabolic, behavioral, and reproductive consequences of chronic androgens in our rat model of PCOS, if allowed to wear off. First, we induced hyperandrogenemia using chronic exposure to elevated levels of dihydrotestosterone (DHT), as it has previously shown metabolic and reproductive patterns similar to women with PCOS [25, 26] ; animals were placed on an obesogenic high-fat diet (HFD). We assessed the effects of DHT and HFD on metabolic parameters (body weight, body composition, and glucose tolerance) and anxiety-like behaviors using the elevated plus maze (EPM). We also determined the pattern of estrous cyclicity as a measure of reproductive health. We then performed vertical sleeve gastrectomy (VSG). We assayed plasma corticosterone and adrenocorticotropic hormone (ACTH) in the absence of stress and during novel environment exposure (stressed condition) as an index of hypothalamic-pituitaryadrenal (HPA) axis function. We hypothesized that VSG surgery would ameliorate the metabolic, behavioral, and reproductive complications in this rat model of PCOS.
Methods

Animals
All procedures for animal use were approved by the University of Cincinnati Institutional Animal Care and Use Committee. Forty-six young (20-24-day-old), female LongEvan rats (Harlan Laboratories, Indianapolis, IN; 35-49 g) were individually housed and maintained in a room on a 12/ 12-h light/dark cycle at 25°C and 50-60 % humidity. Following acclimatization to the facilities, rats were divided into two body weight-and fat mass-matched groups (DHT and placebo). Pellet implantation occurred 4 days after arrival. Animals were given ad libitum access to water and palatable HFD (#D03082706, Research Diets, New Brunswick, NJ; 4.54 kcal/g; 41 % fat) for 6 weeks prior to gastric surgery. Food hoppers placed in each cage were weighed daily or twice weekly to measure food intake. Six weeks post-pellet implantation, animals were divided into four body weight-and fat mass-matched groups of surgical animals: (a) placebo pellet and receiving sham-VSG (S-control; n =10), (b) placebo pellet and receiving VSG surgery (V-control; n =13), (c) DHT pellet and receiving sham-VSG (S-DHT; n =10), or (d) DHT pellet and receiving VSG surgery (V-DHT; n =13). Animals were killed after an additional 6 weeks.
Pellet Implantation
At postnatal days 24-28, anesthetized (isoflurane) female pups were implanted subcutaneously with a 60-day continuous release pellet containing 5.0 mg of 5α-DHT or placebo (Innovative Research of America, Sarasota, FL). This model and dose were chosen based on their ability to induce both ovarian and metabolic characteristics of PCOS [25] and to mimic the hyperandrogenic state in women with PCOS. The DHT pellets were intended to wear off in the postoperative period to garner whether the changes induced by hyperandrogenism are permanent (this has not been previously demonstrated) or able to be modulated by the improved metabolic milieu post-bariatric surgery.
Gastric Surgery
Preoperative Care Four days prior to surgery, body composition was assessed using an Echo magnetic resonance imaging whole-body composition analyzer (EchoMedical Systems, Houston, TX). Animals were solid food-restricted for 24 h and given Osmolite OneCal liquid diet.
VSG VSG was performed as previously described [27] . Briefly, it consisted of a midline abdominal laparotomy with exteriorization of the stomach. The lateral 80 % of the stomach was excised using an ETS 35-mm staple gun, leaving a tubular gastric remnant in continuity with the esophagus. This gastric sleeve was then reintegrated into the abdominal cavity and the abdominal wall was closed in layers.
Sham-VSG An abdominal laparotomy was performed with analogous isolation of the stomach. Light manual pressure was applied to the exteriorized stomach with blunt forceps along a vertical line between the esophageal sphincter and the pylorus. The abdominal wall was closed in layers.
Postoperative Care Following surgery, rats received special care for 3 day, consisting of twice daily subcutaneous injections of warm saline 5 mL, Bupronex® 0.25 mL (0.05 mg/kg), and once daily Metacam® 0.25 mL (0.5 mg/kg). Animals were maintained on Osmolite until food was returned 3 days following surgery. A wire grate was used for 7 days postoperatively to prevent rats from eating bedding.
Body Weight, Composition, and Food Intake Food intake and body weights were measured twice per week for the entirety of the study, with the exception of 10 days following surgery, during which time they were measured daily. Magnetic resonance imaging was performed on all rats at 1, 6, and 12 weeks to determine fat and lean body composition.
Estrous Cycle
The stage of the estrous cycle was determined during five consecutive days at 4, 6, 8, 9, 10, and 12 weeks. Cells were obtained by vaginal lavage and were stained with DipQuick staining kit (Jorgansen Laboratories, Inc., Loveland, CO) for the determination of the estrous cycle phase [28] .
Glucose Tolerance Tests (GTT)
GTT was performed at 5 weeks. Rats were fasted for 8 h. After a baseline blood sample was taken (0 min), 50 % D -glucose (Phoenix Pharmaceutical, St. Joseph, MO) was injected ip or gavaged. Blood glucose was measured at baseline (0), 15, 30, 45, 60, and 120 min after glucose administration on duplicate samples using Accu-chek glucometers and test strips (Roche, Indianapolis, IN). All blood samples were obtained from the tip of the tail vein of freely moving rats. Each rat received a dose of glucose equal to 1.25 g/kg body weight for the ip GTT. Rats were excluded from the data analysis if they did not exhibit a rise in blood glucose of greater than 20 mg/dL in the first 15 min after injection or if they exhibited diarrhea, as this indicates that the glucose injection did not enter the ip cavity. Plasma insulin was measured at 0 and 15 min.
Insulin Tolerance Test (ITT)
Eight-hour fasted rats were injected ip with insulin (0.5 U/kg). Blood glucose was measured at baseline (0), 15, 30, 45, and 60 min after injections with Accu-chek glucometers and test strips. All blood samples were obtained from the tip of the tail vein of freely moving rats.
Diet Preference Testing
During week 5, three pure macronutrient diets (Harlan Teklad, Indianapolis, IN; TD.02521 (carbohydrate), TD.02522 (fat), and TD.02523 (protein)) were presented in separate containers simultaneously for 4 days. Daily food intake of each macronutrient was recorded.
Elevated Plus Maze
An EPM test was performed during week 6. Animals were placed in a holding room approximately 4 h before the onset of the dark phase to acclimate. The challenge was performed at 6 min intervals commencing 15 min after the onset of the dark phase. The apparatus comprised of a PVC maze with two open (40×10) and two enclosed (40×10×20) arms. The arms radiated from a 10-cm central square. The entire apparatus was elevated 60 cm off the floor. For testing, each animal was placed on the center square of the maze facing the same open arm. Behavior was recorded from an overhead ceiling camera for 5 min. Video files were captured and saved for later scoring. The maze was cleaned after each rat was tested. A number of behavioral measures were analyzed, which included standard measures of exploration and anxiety-like behavior as well as additional measures of fear and arousal. Parameters were measured using the Topscan program CleverSys (CleverSys Inc. Reston, VA). Several parameters were scored including arm time (open and closed), arm entries (open and closed), and general locomotor activity.
Novel Environment Challenge
Novel environment challenge was performed on POD 28 (week 11) commencing 2 h after the onset of the light cycle. Each animal was brought from the housing room into the procedure room (T =0), and a blood sample taken quickly by tail clip for later measurement of plasma ACTH and corticosterone. It was then placed immediately into a Plexiglas cylinder approximately 25 cm in diameter and lined with excretory paper for 5 min, after which the animal was returned to the home cage. Additional tail blood samples were quickly collected at 15, 30, 60, and 120 min from the unrestrained rat and returned to the home cage.
Insulin, Lipids, and Plasma Hormone Assays Insulin was measured from fasting plasma. Cholesterol and triglycerides were measured from plasma taken after an 8-h fast. Blood was cold-centrifuged, and plasma was stored at −80°C until they were assessed. Insulin was measured using ELISA (CrystalChem, Inc., Downers Grove, IL). Cholesterol and triglycerides were measured via colorimetric assays using Infinity Reagents (Thermo Fisher Scientific, Inc., Waltham, MA).
Corticosterone was measured by 125 I radioimmunoassay (RIA) kits from ICN Biochemicals (Cleveland, OH). The intraand interassay coefficients of variation are 7.1 and 7.2 %, respectively. ACTH plasma concentration was measured by RIA using 125 I RIA kit from DiaSorin (Stillwater, MN). The limit of detection for this assay was 15 pg/mL, and intra-and interassay coefficients were 6.3 and 6.0 %, respectively. For each assay performed, control samples with known concentrations of hormone (usually low, normal, and high; provided by the manufacturer) were included to assess performance and reliability.
Ovary Morphology
The ovaries were longitudinally and serially sectioned at 10 μm. Sections were mounted on a glass slide, stained with hematoxylin and eosin, and examined under a conventional birefringence microscope.
Statistical Analysis
Data were analyzed using Student's t test, chi-square, or twoway and one-way ANOVA, where appropriate. Significant differences between groups were followed by Tukey or Bonferroni post hoc tests. All results are given as means± SEM. Results were considered statistically significant when p <0.05. Statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA).
Results
DHT Treatment Causes Increased Body Weight, Food Intake, and Fat Mass DHT-treated animals had significantly greater body weight starting 17 days after pellet placement (p <0.001) (Fig. 1a) . This was accompanied by greater food intake by DHT-treated animals starting 14 days post-implant (p <0.01) (Fig. 1b) . The increase in body weight was due to an increase in both lean (p <0.0001) and fat mass (p <0.05), as measured 4 days prior to gastric surgery (Fig. 1c) . There were no differences in body length (naso-anal distance), as measured at the time of gastric surgery and sacrifice. Four weeks after pellet placement, there were no significant differences in glucose tolerance (Fig. 1d) ; however, DHT animals did have significantly higher fasting glucose levels (control 109.9±1.779 SEM; DHT 116.0± 1.217, p <0.01) (Fig. 1e ). There were no differences between groups in regard to insulin levels at baseline and 15 min (Fig. 1f) .
DHT Treatment Causes a Behavioral Phenotype in the EPM
Animals performed in the EPM for a 5-min interval following the onset of the dark phase during week 6. DHT-treated animals spent significantly less time in the open arms (p <0.01) (Fig. 2a) , Fig. 1 DHT treatment causes increased body weight, food intake, fat mass, and impaired fasting glucose. DHT-treated animals had significantly greater body weight starting 17 days after pellet placement (a), accompanied by greater food intake starting at 14 days (b). DHT-treated animals had greater lean and fat mass (c). There were no differences in glucose handling (d); fasting glucose, however, was impaired in DHTtreated animals (e). There were no differences in insulin levels at baseline or 15 min (f). All data are presented as mean±SEM, *p <0.05, **p <0.01, ***p <0.001 (Fig. 2b) , and traveled less distance in the open arms (p <0.05) (Fig. 2c) . No differences emerged in the latency to enter the open arms or the velocity traveled in the open arms (Fig. 2d) . Anxiety-related behavior was thus increased in DHT-treated animals.
DHT Treatment Does Not Result in Food Preference Differences
When presented with a choice of three pure macronutrient diets (carbohydrate, fat, and protein), no differences were observed between the DHT and control groups. All rats consumed the most kilocalories in fat followed by carbohydrate and then protein. There was a significant difference in total kilocalories consumed, with DHT rats consuming less than controls during this 4-day experiment (p <0.05) (data not shown). This decrease in consumption varied from the remainder of the study, when DHT rats consistently consumed more than the controls.
VSG Resulted in Loss of Excess Body Weight and Fat Mass Gained on HFD
Following surgery, V-control and V-DHT animals lost a significant amount of body weight compared to S-control and S-DHT animals starting 1 week after surgery (p <0.001) (Fig. 3a) . V-DHT animals maintained a lower body weight than S-DHT animals for the entirety of the experiment (p <0.05). Body composition was measured at 31 days following surgery. S-DHT and V-DHT animals maintained higher lean (p <0.0001) and fat mass (p <0.05) than their control counterparts. V-control and V-DHT had higher lean mass than the S-control and S-DHT animals (p <0.05), respectively, while demonstrating lower fat mass (p <0.0001) (Fig. 3b) . Average daily food intake was decreased in the V-control and V-DHT animals for the first 4 weeks postoperatively (p <0.05) (Fig. 3c) . There was no hyperphagia by VSG animals once recovered, thereby VSG animals cumulatively consumed less than their sham counterparts over the entirety of the experiment (p <0.0001), while DHT animals cumulatively consumed more than controls (p <0.5) (Fig. 3d) .
At 2 weeks postoperatively, although there was no improvement in glucose tolerance curves, an improvement in fasting glucose levels was observed in VSG groups (p <0.001), and levels were lower in control groups compared to DHT (p <0.05) (Fig. 3e ). There were no differences in fasting insulin levels (Fig. 3f) . VSG animals had significant improvement in fasting triglyceride levels (p <0.0001) (Fig. 3g) ; fasting cholesterol levels did not differ. There were no differences in glucose levels groups during an insulin tolerance test (Fig. 3h) . Fig. 3 VSG results in overall metabolic improvements. Postoperative body weights were lower in VSG animals as compared to shams (a). VSG animals had higher lean mass and lower fat mass than shams, while DHT animals maintained higher lean and fat mass than controls (b). Average daily food intake was decreased in the VSG animals for the first 4 weeks postoperatively (c). VSG animals cumulatively consumed less than shams, with DHT animals cumulatively consuming more than controls (d). VSG animals had improved fasting glucose with DHT animals maintaining higher fasting glucose levels than controls (e). No differences existed in fasting insulin levels (f), and VSG animals had improved triglyceride levels irrespective of group (g). No differences in blood glucose levels were observed during the insulin tolerance test. All data are presented as mean±SEM. Unique symbol notations (for example, a versus b) denote statistical main effects by that variable (that is drug treatment or surgery). Same symbol notations denote no statistical main effect by that variable (that is, drug treatment or surgery). Symbols do not denote significant differences in post hoc comparisons VSG Causes Blunted Corticosterone Response to Stress Four weeks after surgery, a novel environment stress test demonstrated that treatment affected both basal and stressinduced corticosterone levels. A blunted corticosterone response was observed in V-DHT animals at 15 (p <0.001), 30 (p <0.001), and 60 min (p <0.01) (Fig. 4a) . The AUC was lower in both DHT groups compared to controls (p <0.001) (Fig. 4b) , whereas basal corticosterone levels were lower in both VSG groups compared to sham animals (p <0.0001) (Fig. 4c ). There were no differences in ACTH levels at any of the time points (Fig. 4d) , in their ACTH AUCs (Fig. 4e) , nor in basal ACTH levels (Fig. 4f) .
DHT Treatment Caused Hirsutism and Disrupted Estrous Cyclicity
The animals treated with DHT showed longer body hair, with coats resembling those of male rats. They also demonstrated hirsutism, evident at the vaginal openings (Fig. 5a, b) . Prior to VSG surgery, all DHT rats were acyclic (chronic diestrous). Cyclicity was eventually restored. By 2 weeks postoperatively, S-DHT animals began to regain normal cyclicity. V-DHT animals were the slowest to regain normal cyclicity, with no statistically significant differences (chi-squared) in cyclicity by 4 weeks postoperatively (Fig. 5c) . Examination of representative HE-stained ovaries from each of the animal groups was also indicative of normal cyclicity, as they showed corpora lutea and follicles at various stages of development (Fig. 6a-d) .
Prior to surgery, DHT levels were threefold higher in those with DHT pellets implanted (p <0.0001), with no differences in levels by 2 weeks following surgery (Fig. 5d) . This was consistent with the predicted timing of the pellets wearing off (60 days). The DHT-treated animal groups had smaller ovaries as compared to the control groups (p <0.0001) (Fig. 5e) .
Discussion
There are no known cures for PCOS. Though diet and exercise are effective for short-term body weight loss, bariatric surgery results in durable, long-term loss of body weight and remission of metabolic comorbidities of obesity; it is unknown whether bariatric surgery is effective in ameliorating the metabolic, stress-related psychiatric, and reproductive disorders of PCOS. Here we demonstrated that DHT with HFD results in increased body weight and body fat, impaired fasting glucose, hirsutism, irregular cycles, and anxiety that mimics Fig. 4 VSG causes a blunted corticosterone response to stress. A novel environment stress test showed a blunted corticosterone response in V-DHT animals (a). The AUC was lower in DHT animals vs. controls (b). Basal corticosterone levels were lower in VSG animals (c). There were no differences in ACTH levels at any time point (d), in ACTH AUCs (e) nor in basal ACTH (f). All data are presented as mean±SEM, **p <0.01, ***p <0.001.
Unique symbol notations (for example, a versus b) denote statistical main effects by that variable (that is, drug treatment or surgery). Same symbol notations denote no statistical main effect by that variable (that is, drug treatment or surgery). Symbols do not denote significant differences in post hoc comparisons many of the aspects of human PCOS. VSG performed in this model of PCOS effectively reduced food intake, body weight, and body fat with improved fasting glucose and triglyceride levels. Additionally, VSG induced lower basal stress hormone levels and attenuated stress responsivity in V-DHT animals. Following the postoperative waning of the DHT pellet, DHT levels in all groups returned to baseline control levels, and normal cyclicity returned to the DHT rats. The return to normal cycling was slower in the VSG animals as compared to shams, but this difference was transient and there were no differences after 2 weeks from when the pellet ceased to deliver DHT.
One of the biggest challenges in studying PCOS in an animal model is the heterogeneity of human phenotypes with an unknown etiology. DHT pellets provide an exogenous androgen source with constant levels not subjected to the same variability as human physiologic androgens. Nevertheless, this model has been used extensively [26, 29] . Our group has previously shown that PCOS rats who underwent VSG lost body weight and adiposity; estrous cyclicity, however, was not restored in the face of continuous exogenous DHT administration in lean rats maintained on standard rodent chow [30] . Simply, the overriding effects of continuous DHT treatment could not be reversed. Since human studies have shown that hyperandrogenism is ameliorated by bariatric surgery [24] , our model sought to recreate these improved conditions. Previously, DHT treatment has only been done in chow-fed animals which has allowed for understanding of the openings (a, b) . Prior to VSG surgery and while DHT pellets were active, DHT animals were acyclic. By 2 weeks post-VSG, S-DHT animals began to regain normal cyclicity with no differences between groups by 4 weeks post-VSG (c). DHT levels were threefold higher in those implanted with DHT pellets, with no differences in levels by 2 weeks post-VSG (d). DHT animals had smaller ovaries (e). All data are presented as mean±SEM, ***p <0.001. Unique symbol notations (for example, a versus b) denote statistical main effects by that variable (that is, drug treatment or surgery). Same symbol notations denote no statistical main effect by that variable (that is, drug treatment or surgery). Symbols do not denote significant differences in post hoc comparisons contribution of hyperandrogenism alone to the human phenotype. Our modified model utilized HFD to allow for these obesity-induced manifestations that may be more similar to the situation for many PCOS patients.
Metabolic improvements observed from VSG in the PCOS model included reduced food intake, body weight, and adiposity, with improved fasting glucose and triglyceride levels. These results suggest that women with PCOS who undergo VSG will have significant metabolic improvements. There is no literature to date regarding women with PCOS undergoing VSG; nonetheless, several studies have shown similar metabolic impacts of RYGB and VSG on insulin sensitivity [31] [32] [33] and lipids [33, 34] . Despite the awareness that insulin resistance and hyperinsulinemia are key features of PCOS, the etiology and mechanisms of improvement are not fully understood.
While obesity is associated with PCOS and exacerbates many of its comorbidities, the etiology of the obesity observed in many PCOS patients is unclear. One hypothesis is that women with PCOS may have altered dietary consumption and food preferences [35] . Accurate human data are difficult to obtain due to reporting error (underestimation and change of diet knowing that they are being evaluated and recall bias). When given a choice of macronutrients, our PCOS animals did not differ from controls in a preference for fat, carbohydrate, or protein, suggesting that elevated androgens are not sufficient to drive a significant change in preference for fat or carbohydrate. These results are consistent with one similar human study [36] . Interestingly, the PCOS animals consumed fewer kilocalories during this experiment in contrast to the remainder of the study. One potential explanation is that the change of diet was in and of itself a stressor to which the PCOS animals had a more difficult time coping.
Women with PCOS have been shown to have altered stress responses [37] and an association with psychosocial problems, including depression, anxiety, chronic stress, and reduced quality of life [38, 39] . The mechanism underlying these associations is unknown. One explanation is that the psychological impairments are caused by the distress induced by PCOSassociated symptoms (e.g., obesity, hirsutism, infertility, etc.); another explanation is an organic cause, such as hyperandrogenism. While some studies have shown a correlation between androgen levels and anxiety [40] , others have not [41] . Our results support an organic contribution, as this model eliminates the confounders of psychosocial variables and demonstrates a clear relationship between hyperandrogenism and anxiety. Psychosocial contributions affecting women with PCOS, however, are not testable in animal models and may also play a significant role.
Plasma glucocorticoid levels have been used as a biomarker of physiological and psychological stressors, as stressful stimuli cause an increase in activity in the HPA axis, leading to increased glucocorticoid secretion [42, 43] . V-DHT animals had a reduced corticosterone response to a novel environment stress. Remarkably, all VSG animals had lower basal corticosterone levels, but there were no differences in basal or acute stressed ACTH levels. This implies that the decreased corticosterone levels are the result of a primary adrenal difference rather than differences at the level of the hypothalamus or pituitary. Since women with PCOS have demonstrated increased stress-induced HPA axis reactivity [37] , VSG may serve to ameliorate this exaggerated response. The lower corticosterone levels post-VSG may infer further metabolic benefit given that cortisol promotes central fat accumulation and insulin resistance [44, 45] .
Reproductive function was impaired in the DHT-treated animals, similar to women with PCOS and hyperandrogenemia. After resolution of the hyperandrogenemia and surgically induced weight loss, the V-DHT animals slowly regained normal cyclicity; this is similar to humans post-bariatric surgery who regained normal menstrual patterns [23, 24] . They did not, however, regain normal reproductive function faster than sham animals, as hypothesized. The human literature regarding weight loss and reproductive function is variable; some report a weight loss of as little as 5 % body weight improving menstrual cyclicity and ovulation rates [46] [47] [48] and others report limited improvement [49] . One suggested mechanism for this variation is that hyperinsulinemia in women with obesity contributes to anovulation [50, 51] and resumption of ovulation is mediated by reduced insulin resistance [50, 52] . Insulin signaling has a role in ovarian steroidogenesis, follicle development, and granulosa cell proliferation [51, 53, 54] . Both obese and lean women with PCOS have greater insulin resistance than weight-matched controls [55] . This hypothesis is further supported by the evidence that metformin improves ovulation, as reported in a recent Cochrane review [56] .
Another consideration is that the animals remained on HFD through the entirety of the study. By postoperative week 4 (i.e., week 12 on HFD), even S-control animals exhibited a decline in normal cyclicity. Little is understood about the effects of diet on fertility. One study suggests that dietary trans fatty acids increase the risk of ovulatory infertility [57] . The dietary intake of high levels of saturated fatty acids is positively associated with the development of insulin resistance [58] . Another study showed that female rats with HFDinduced obesity developed systemic insulin resistance, hyperinsulinemia, and an extended estrous cycle with altered ovarian insulin signaling [59] .
Conclusions
There are a variety of treatments available for women with PCOS. Most of the treatments, however, are symptom-based and do not address the metabolic, behavioral, and reproductive problems simultaneously. We have shown that VSG can improve many manifestations of PCOS in a comprehensive manner, including weight loss, glucose homeostasis, stressinduced behavior, and menstrual regularity when the overriding hyperandrogenism is removed. Two reports in humans suggest that RYGB may ameliorate the symptoms of PCOS [60, 61] and improve fertility [61] . These human studies as well as our rodent studies suggest that the amelioration of the PCOS symptoms is secondary to weight loss and improved glucose tolerance following bariatric surgery. Further investigation will be needed to understand the mechanisms involved and the effects of VSG in humans with PCOS.
